Literature DB >> 21930089

Application of metabolomics to prostate cancer.

Bruce J Trock1.   

Abstract

The prostate has long been known to exhibit unique metabolite profiles. In the last decade, advances in nuclear magnetic resonance spectroscopy and mass spectrometry have been applied toward identifying metabolic alterations in prostate cancer that may provide clinically useful biomarkers. As with genomics and proteomics, advances in technology and bioinformatics have led to the application of metabolomic profiling to prostate cancer-the high throughput evaluation of a large complement of metabolites in the prostate and how they are altered by disease perturbations. Recently, high profile publications have drawn attention to the potential of metabolomic analysis to identify biomarkers for early detection or disease progression from readily accessible body fluids as well as tissue specimens from biopsy and surgery. This review will examine applications of metabolomics to prostate cancer and highlight clinical associations and potential challenges.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21930089      PMCID: PMC3180907          DOI: 10.1016/j.urolonc.2011.08.002

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  44 in total

1.  Serum sarcosine is not a marker for prostate cancer.

Authors:  Eduard A Struys; Annemieke C Heijboer; Jeroen van Moorselaar; Cornelis Jakobs; Marinus A Blankenstein
Journal:  Ann Clin Biochem       Date:  2010-03-16       Impact factor: 2.057

2.  Sarcosine, folate metabolism and prostate cancer--is there a link?

Authors:  Conrad Wagner; Zigmund Luka
Journal:  J Urol       Date:  2010-12-17       Impact factor: 7.450

3.  Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy.

Authors:  Mark G Swanson; Andrew S Zektzer; Z Laura Tabatabai; Jeffry Simko; Samson Jarso; Kayvan R Keshari; Lars Schmitt; Peter R Carroll; Katsuto Shinohara; Daniel B Vigneron; John Kurhanewicz
Journal:  Magn Reson Med       Date:  2006-06       Impact factor: 4.668

Review 4.  Tackling the widespread and critical impact of batch effects in high-throughput data.

Authors:  Jeffrey T Leek; Robert B Scharpf; Héctor Corrada Bravo; David Simcha; Benjamin Langmead; W Evan Johnson; Donald Geman; Keith Baggerly; Rafael A Irizarry
Journal:  Nat Rev Genet       Date:  2010-09-14       Impact factor: 53.242

5.  Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.

Authors:  Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

6.  Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.

Authors:  D-L Cao; D-W Ye; Y Zhu; H-L Zhang; Y-X Wang; X-D Yao
Journal:  Prostate Cancer Prostatic Dis       Date:  2011-02-15       Impact factor: 5.554

7.  Citrate concentrations in human seminal fluid and expressed prostatic fluid determined via 1H nuclear magnetic resonance spectroscopy outperform prostate specific antigen in prostate cancer detection.

Authors:  Eric E Kline; Eric G Treat; Tiffany A Averna; Michael S Davis; Anthony Y Smith; Laurel O Sillerud
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

8.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

Review 9.  Concepts of citrate production and secretion by prostate. 1. Metabolic relationships.

Authors:  L C Costello; R B Franklin
Journal:  Prostate       Date:  1991       Impact factor: 4.104

10.  Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.

Authors:  Susan L Ettinger; Richard Sobel; Tanis G Whitmore; Majid Akbari; Dawn R Bradley; Martin E Gleave; Colleen C Nelson
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  48 in total

Review 1.  NMR-based metabolomics studies of human prostate cancer tissue.

Authors:  Ana Rita Lima; Joana Pinto; Maria de Lourdes Bastos; Márcia Carvalho; Paula Guedes de Pinho
Journal:  Metabolomics       Date:  2018-06-18       Impact factor: 4.290

2.  Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer.

Authors:  Shahriar Koochekpour
Journal:  Asian J Androl       Date:  2013-01-14       Impact factor: 3.285

Review 3.  Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.

Authors:  Eva-Margarete Spur; Emily A Decelle; Leo L Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-03       Impact factor: 9.236

4.  1-stearoylglycerol is associated with risk of prostate cancer: results from serum metabolomic profiling.

Authors:  Alison M Mondul; Steven C Moore; Stephanie J Weinstein; Satu Männistö; Joshua N Sampson; Demetrius Albanes
Journal:  Metabolomics       Date:  2014-10-01       Impact factor: 4.290

Review 5.  Overview of mass spectrometry-based metabolomics: opportunities and challenges.

Authors:  G A Nagana Gowda; Danijel Djukovic
Journal:  Methods Mol Biol       Date:  2014

Review 6.  Cancer in the crosshairs: targeting cancer metabolism with hyperpolarized carbon-13 MRI technology.

Authors:  Cornelius von Morze; Matthew E Merritt
Journal:  NMR Biomed       Date:  2018-06-05       Impact factor: 4.044

Review 7.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

8.  Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells.

Authors:  Shahriar Koochekpour; Sunipa Majumdar; Gissou Azabdaftari; Kristopher Attwood; Ray Scioneaux; Dhatchayini Subramani; Charles Manhardt; Giovanni D Lorusso; Stacey S Willard; Hillary Thompson; Mojgan Shourideh; Katayoon Rezaei; Oliver Sartor; James L Mohler; Robert L Vessella
Journal:  Clin Cancer Res       Date:  2012-10-16       Impact factor: 12.531

9.  Biomarker Discovery and Translation in Metabolomics.

Authors:  G A Nagana Gowda; D Raftery
Journal:  Curr Metabolomics       Date:  2013

Review 10.  Translational metabolomics in cancer research.

Authors:  Nathaniel W Snyder; Clementina Mesaros; Ian A Blair
Journal:  Biomark Med       Date:  2015-09-01       Impact factor: 2.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.